Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Regeneron Pharmaceuticals Inc has a consensus price target of $1053.76 based on the ratings of 31 analysts. The high is $1300 issued by Guggenheim on August 2, 2024. The low is $650 issued by B of A Securities on March 29, 2023. The 3 most-recent analyst ratings were released by RBC Capital, Cantor Fitzgerald, and Cantor Fitzgerald on September 17, 2024, September 16, 2024, and September 9, 2024, respectively. With an average price target of $1104 between RBC Capital, Cantor Fitzgerald, and Cantor Fitzgerald, there's an implied -3.58% downside for Regeneron Pharmaceuticals Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Regeneron Pharmaceuticals (NASDAQ:REGN) was reported by RBC Capital on September 17, 2024. The analyst firm set a price target for $1282.00 expecting REGN to rise to within 12 months (a possible 11.96% upside). 58 analyst firms have reported ratings in the last year.
The latest analyst rating for Regeneron Pharmaceuticals (NASDAQ:REGN) was provided by RBC Capital, and Regeneron Pharmaceuticals reiterated their outperform rating.
The last upgrade for Regeneron Pharmaceuticals Inc happened on January 12, 2024 when RBC Capital raised their price target to $1076. RBC Capital previously had a sector perform for Regeneron Pharmaceuticals Inc.
The last downgrade for Regeneron Pharmaceuticals Inc happened on June 28, 2023 when Canaccord Genuity changed their price target from $953 to $720 for Regeneron Pharmaceuticals Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Regeneron Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Regeneron Pharmaceuticals was filed on September 17, 2024 so you should expect the next rating to be made available sometime around September 17, 2025.
While ratings are subjective and will change, the latest Regeneron Pharmaceuticals (REGN) rating was a reiterated with a price target of $1282.00 to $1282.00. The current price Regeneron Pharmaceuticals (REGN) is trading at is $1145.03, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.